Literature DB >> 23002349

Hyperthermia inhibits hypoxia-induced epithelial-mesenchymal transition in HepG2 hepatocellular carcinoma cells.

Guang-Jin Yuan1, Qian-Wen Li, Shun-Lin Shan, Wu-Ming Wang, Sen Jiang, Xi-Ming Xu.   

Abstract

AIM: To investigate the effect of hyperthermia on hypoxia-induced epithelial-mesenchymal transition (EMT) in HepG2 hepatocellular carcinoma (HCC) cells, and its mechanism.
METHODS: Cells were treated with hyperthermia at 43 °C for 0.5 h, followed by incubation under hypoxic or normoxic conditions for 72 h. Cell morphology was observed. Expressions of E-cadherin and vimentin were determined by immunofluorescence assay or Western blot. The protein and mRNA expressions of Snail were also determined by Western blot and reverse transcription-polymerase chain reaction. Cell migratory capacity was evaluated.
RESULTS: Hypoxia induced EMT in HepG2 cells, which was evidenced by morphological, molecular and functional changes, including the formation of a spindle shape and the loss of cell contact. The expression of E-cadherin was decreased but the expression of vimentin was increased; also, the migratory capability was increased by 2.2 ± 0.20-fold as compared with normoxia. However, those effects were inhibited by hyperthermia pretreatment. Furthermore, protein synthesis and mRNA expression of Snail in the cells were enhanced by hypoxia as compared with normoxia, and also significantly inhibited by hyperthermia pretreatment.
CONCLUSION: Hyperthermia may inhibit hypoxia-induced EMT in HepG2 HCC cells, and the mechanism may involve inhibition of induced expression of Snail.

Entities:  

Keywords:  Epithelial-mesenchymal transition; Hepatocellular carcinoma; Hyperthermia; Hypoxia; Snail

Mesh:

Substances:

Year:  2012        PMID: 23002349      PMCID: PMC3442218          DOI: 10.3748/wjg.v18.i34.4781

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  24 in total

Review 1.  The snail superfamily of zinc-finger transcription factors.

Authors:  M Angela Nieto
Journal:  Nat Rev Mol Cell Biol       Date:  2002-03       Impact factor: 94.444

2.  Heat shock-mediated transient increase in intracellular 3',5'-cyclic AMP results in tumor specific suppression of membrane type 1-matrix metalloproteinase production and progelatinase A activation.

Authors:  Y Sawaji; T Sato; M Seiki; A Ito
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

3.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

4.  E-Cadherin loss associated with EMT promotes radioresistance in human tumor cells.

Authors:  Guido Lammering; Marc Vooijs; Jan Theys; Barry Jutten; Roger Habets; Kim Paesmans; Arjan J Groot; Philippe Lambin; Brad G Wouters
Journal:  Radiother Oncol       Date:  2011-06-15       Impact factor: 6.280

Review 5.  Epidemiology and natural history of hepatocellular carcinoma.

Authors:  Katherine A McGlynn; W Thomas London
Journal:  Best Pract Res Clin Gastroenterol       Date:  2005-02       Impact factor: 3.043

Review 6.  Hyperthermia in combined treatment of cancer.

Authors:  P Wust; B Hildebrandt; G Sreenivasa; B Rau; J Gellermann; H Riess; R Felix; P M Schlag
Journal:  Lancet Oncol       Date:  2002-08       Impact factor: 41.316

Review 7.  Tumour hypoxia: impact on biology, prognosis and treatment of solid malignant tumours.

Authors:  M Weinmann; C Belka; L Plasswilm
Journal:  Onkologie       Date:  2004-02

Review 8.  Transcriptional regulation of cadherins during development and carcinogenesis.

Authors:  Héctor Peinado; Francisco Portillo; Amparo Cano
Journal:  Int J Dev Biol       Date:  2004       Impact factor: 2.203

Review 9.  Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies.

Authors:  Aoife M Shannon; David J Bouchier-Hayes; Claire M Condron; Deirdre Toomey
Journal:  Cancer Treat Rev       Date:  2003-08       Impact factor: 12.111

10.  Anti-angiogenic action of hyperthermia by suppressing gene expression and production of tumour-derived vascular endothelial growth factor in vivo and in vitro.

Authors:  Y Sawaji; T Sato; A Takeuchi; M Hirata; A Ito
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

View more
  5 in total

1.  Effects of melatonin on HIF-1α and VEGF expression and on the invasive properties of hepatocarcinoma cells.

Authors:  Jucimara Colombo; João Marcos Wolf Maciel; Lívia Carvalho Ferreira; Renato Ferreira DA Silva; Debora Aparecida Pires Zuccari
Journal:  Oncol Lett       Date:  2016-05-18       Impact factor: 2.967

2.  Intraperitoneal perfusion of cytokine-induced killer cells with local hyperthermia for advanced hepatocellular carcinoma.

Authors:  Xiao-Pu Wang; Meng Xu; Hong-Fei Gao; Jian-Fu Zhao; Ke-Cheng Xu
Journal:  World J Gastroenterol       Date:  2013-05-21       Impact factor: 5.742

3.  The inhibitory effect of heat treatment against epithelial-mesenchymal transition (EMT) in human pancreatic adenocarcinoma cell lines.

Authors:  Reiko Kimura-Tsuchiya; Takeshi Ishikawa; Satoshi Kokura; Katsura Mizushima; Satoko Adachi; Manabu Okajima; Tatsuzo Matsuyama; Tetsuya Okayama; Naoyuki Sakamoto; Kazuhiro Katada; Kazuhiro Kamada; Kazuhiko Uchiyama; Osamu Handa; Tomohisa Takagi; Nobuaki Yagi; Yuji Naito; Yoshito Itoh
Journal:  J Clin Biochem Nutr       Date:  2014-05-13       Impact factor: 3.114

4.  Sorafenib and locoregional deep electro-hyperthermia in advanced hepatocellular carcinoma: A phase II study.

Authors:  Gennaro Gadaleta-Caldarola; Stefania Infusino; Ida Galise; Girolamo Ranieri; Gianluca Vinciarelli; Vito Fazio; Rosa Divella; Antonella Daniele; Gianfranco Filippelli; Cosmo Damiano Gadaleta
Journal:  Oncol Lett       Date:  2014-07-24       Impact factor: 2.967

Review 5.  Nanomaterials as Inhibitors of Epithelial Mesenchymal Transition in Cancer Treatment.

Authors:  Marco Cordani; Raffaele Strippoli; Álvaro Somoza
Journal:  Cancers (Basel)       Date:  2019-12-19       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.